The Latest Breaking News from Lilly

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

Eli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

Eli Lilly stock popped Wednesday after the company's weight-loss drug significantly reduced nighttime sleep apnea events.

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Eli Lilly stock is Wednesday's IBD Stock Of The Day. Shares are forming a flat base as competition mounts for its weight-loss drug, Zepbound.

Novo Nordisk and Eli Lilly stocks dipped Thursday after Medicare said it could pay for weight-loss drugs for some members.

Eli Lilly said Wednesday it tapped Amazon.com's pharmacy division to deliver some of its prescription meds, including its weight-loss drug.

Novo Nordisk said Friday its weight-loss drug gained FDA approval to cut the risk of heart attack and strokes. Novo Nordisk stock dipped.

Eli Lilly's highly anticipated Alzheimer's drug has been held back for further review by regulators, the US pharmaceutical giant said Friday, in a blow for patients with the devastating brain disorder.

Biogen stock jumped Friday after the FDA delayed its approval decision on Eli Lilly's rival Alzheimer's treatment, donanemab.